Propanc Biopharma, Inc.

Latest News

Sep 27, 2017

Propanc Biopharma Highlights Therapeutic Potential of PRP

PRP Reverses the EMT Process, Stops Tumor Progression and Metastasis and Represses CSCs MELBOURNE, AUSTRALIA -- (Marketwired) -- 09/27/17 -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or…

View All Press Releases

Aug 30, 2017

Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies

Aug 2, 2017

Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study

Jul 27, 2017

Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP
Latest Publication In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation View All Publications
Seethru Equity